PapersPMID:33081717
A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
What moved
1 findingHow to read these marks →“In addition, patients in the β-cryptoxanthin group only showed a greater 12-week reduction in serum level of ALT, compared to those in the control group (for ALT: mean difference − 9.6 IU/L; p = 0.005).”
- Study
- RCT
- Duration
- 3 months
- Effect
- −9.6 mean difference
- Dose studied
- 6 mg/day β-cryptoxanthin, one 600 mg capsule (powder 1% β-cryptoxanthin, 99% starch) daily after dinner, 12 weeks
- Population
- Iranian overweight/obese adults with moderate-to-severe non-alcoholic fatty liver disease; the same 500 kcal/day-deficit normal-protein diet in both arms; intention-to-treat, multivariable-adjusted ANCOVA contrast against the control arm
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- overweight/obese adult non-alcoholic fatty liver disease (NAFLD) outpatients with grade 2-3 hepatic steatosis, Ahvaz, Iran
- Participants
- 92
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 33